logo ☰

Faculty Directory

Dr. Shyam Lal M

Scientist-C

Our research thrusts is to engineering delivery systems for poorly water soluble drugs towards therapeutic clinical applications primarily, against neglected infectious diseases (Visceral Leishmaniasis). We focus on the development of nanomedicines based on biological nanomaterials with considerable priority on interface between in vitro and in vivo studies and how logically-designed and engineered drug delivery systems can be translated into clinically-effective therapeutics.

CONTACT INFORMATION :

Research Interest

  • Developing targeting moieties for nanoparticle drug delivery towards visceral leishmaniasis.
    Biocompatible and Biodegradable nanoparticles for therapeutics: A Nano approach.
    Understanding the interactions of nanomaterials and biological system.

Research Highlights

empty! record not found

PhD Students

  • MS. KANIKA ARORA

    Email: kanika.ph21215@inst.ac.in

    Reg. No.: PH21215

    Working Since Aug, 2021

  • Mr. AAQIB JAVAID

    Email: aaqib.ph20211@inst.ac.in

    Reg. No.: PH20211

    Working Since Aug, 2020

  • Mrs. Shabi Parvez

    Email: shabi.ph15219@inst.ac.in

    Reg. No.: PH15219

    Working Since Jan, 2016

  • Ms. Archana Karole

    Email: archana.ph19205@inst.ac.in

    Reg. No.: PH19205

    Working Since Aug, 2019

  • Ms. Aakriti Singh

    Email: aakriti.ph17203@inst.ac.in

    Reg. No.: PH17203

    Working Since Aug, 2017

empty! record not found

  1. Coalition of biological agent (melatonin) with chemotherapeutic agent (amphotericin B) for combating visceral leishmaniasis via oral administration of modified solid lipid nanoparticles: Parvez S, Yadagiri G,Arora K, Javaid A,Kushwaha A.K.,Singh O.P.,Sundar S,Mudavath S.L*., (2021) ACS Biomaterials Science & Engineering, . DOI: https://doi.org/10.1021/acsbiomaterials.1c00859

  2. Downshifting and upconversion dual mode emission from lanthanide doped GdPO4 nanorods for unclonable anti-counterfeiting: Pushpendra, I. Suryawanshi, S. Srinidhi, S. Singh, R. Kalia, R. K. Kunchala, S.L. Mudavath, B.S. Naidu*, (2021) Mater. Today Commun., 26: 102144. DOI: 10.1016/j.mtcomm.2021.102144

  3. Detection of Latent Fingerprints using Luminescent Gd0.95Eu0.05PO4 Nanorods: Pushpendra, I. Suryawanshi, R. Kalia, R. K. Kunchala, S.L. Mudavath, B.S. Naidu*, (2021) J. Rare Earths, . DOI: 10.1016/j.jre.2021.01.015

  4. Nanodiagnostics in Leishmaniasis: A New Frontier for Early Elimination: Mallikarjuna Rao Gedda, Prasoon Madhukar, Ashish Shukla, Shyam Lal Mudavath, Onkar Nath Srivastava, Om Prakash Singh and Shyam Sundar, (2020) WIREs Nanomedicine and Nanobiotechnology, Accepted: 1-22. DOI: 10.1002/wnan.1675

  5. Recuperating the biopharmaceutical aspects of amphotericin B and paromomycin using a chitosan functionalized nanocarrier via oral route for enhanced anti-leishmanial activity: Shabi Parvez, Ganesh Yadagiri, Archana Karole, Om Prakash Singh, Anurag Verma, Shyam Sundar and Shyam Lal Mudavath*, (2020) Front. Cell. Infect. Microbiol., . DOI: 10.3389/fcimb.2020.570573

  6. Formulation, characterization, and in vitro anti-leishmanial evaluation of amphotericin b loaded solid lipid nanoparticles coated with vitamin B12-stearic acid conjugate: Aakriti Singh‡, Ganesh Yadagiri‡, Shabi Parvez, Om Prakash Singh, Anurag Verma, Shyam Sundar, Shyam Lal Mudavath*, (2020) Materials Science & Engineering C, 117: 111279. DOI: 10.1016/j.msec.2020.111279

  7. Evaluation of Safety and Antileishmanial efficacy of Amine Functionalized Carbon-based Composite Nanoparticle appended with Amphotericin B: An In vitro and Preclinical Study: Mallikarjuna Rao Gedda,Prasoon Madhukar,Alok Kumar Vishwakarm,Vimal Verma,Anurag Kumar Kushwaha,Ganesh Yadagiri,Shyam Lal Mudavath,Om Prakash Singh,Onkar Nath Srivastava,Shyam Sundar, (2020) Front. Chem., . DOI: https://doi.org/10.3389/fchem.2020.00510

  8. Improvising anti-leishmanial activity of Amphotericin B and Paromomycin using co-delivery in D-α-tocopheryl polyethylene glycol 1000 succinate (TPGS) tailored Nano-lipid carrier system: Shabi Parvez, Ganesh Yadagiri, Aakriti Singh, Archana Karole, Om Prakash Singh, Shyam Sundar,Shyam Lal Mudavath*, (2020) Chemistry and Physics of Lipids, 231: 104946. DOI: 10.1016/j.chemphyslip.2020.104946

  9. Sensible graphene oxide differentiates macrophages and Leishmania: A Bio-nano interplay in attenuating intracellular parasite: Aakriti Singh‡, Sandeep Sharma‡, Ganesh Yadagiri, Shabi Parvez, Nikhil Koratkar, Om Prakash Singh, Shyam Sundar, Vijayakumar Shanmugam* and Shyam Lal Mudavath*, (2020) RSC Advances, 10: 27502–27511. DOI: DOI: 10.1039/d0ra04266h

  10. Modified solid lipid nanoparticles encapsulated with Amphotericin B and Paromomycin: An effective oral combination against experimental murine visceral leishmaniasis: Shabi Parvez‡, Ganesh Yadagiri‡, Mallikarjuna Rao Gedda, Aakriti Singh, Om Prakash Singh, Anurag Verma, Shyam Sundar, Shyam Lal Mudavath*, (2020) Scientific Reports, 10: 12243. DOI: https://doi.org/10.1038/s41598-020-69276-5

  11. Enkephalins as a therapeutic intervention for visceral leishmaniasis: Ganesh Yadagiri,Shyam Lal Mudavath*, (2020) Medical Hypotheses, 144: 109956. DOI: doi.org/10.​1016/​j.​mehy.​2020.​109956

  12. Envisioning the innovations in nanomedicine to combat visceral leishmaniasis: for future theranostic application: Om Prakash Singh, Mallikarjuna Rao Gedda, Shyam Lal Mudavath, Onkar Nath Srivastava, Shyam Sundar, (2019) Nanomedicine, 14: 1911-1927. DOI: 10.2217/nnm-2018-0448

  13. Mannose-conjugated curcumin-chitosan nanoparticles: Efficacy and toxicity assessments against Leishmania donovani: Chaubey P, Mishra B, Patel RR, Chaurasia S, Sundar S, Suvarna V, Monteiro M, (2018) Int J Biol Macromol, 111: 109-120. DOI: 10.1016/j.ijbiomac.2017.12.143

  14. Galactosylated Chitosan for Enhanced and Efficient Antimicrobial and Antileishmanial Activities: A Novel Approach: Vishwakarma N.K.; Patel V.K.; Gundampati R.K.; Mudavath S.L.; Gupta T.; Ramesh K.; Jana K.K.; Dutta P.K.; Maiti P.; Mishra N.; Jagannadham M.V.; Sundar S.; Ray B., (2015) Asian Chitin J, 11: 11-18. DOI: NA

  15. Characterization and evaluation of amine modified graphene Amphotericin B for the treatment of visceral leishmaniasis: in vivo and in vitro studies: Talat M, Rai M, Srivastava ON, Sundar S, (2014) Drug Design, Development and Therapy, 8: 1235-47. DOI: 10.2147/DDDT.S63994

  16. In vivo assessment of antileishmanial property of 4-(4, 4, 8-Trimethyl 7-oxo-3-oxabicyclo [3.3.1] non-2-yl)-benzoic acid methyl ester, an oxabicyclo [3.3.1] nonanones, in hamster model: Prakash Saudagar, Pipas Saha, Anil K. Saikia,Vikash Kumar Dubey,Shyam Sundar, (2014) Letters in Drug Design & Discovery, 11: 937-939. DOI: 10.2174/1570180811666140423203826

  17. Comparative Evaluation of Blood and Serum Samples in Rapid Immunochromatographic Tests for Visceral Leishmaniasis: Kumar D, Khanal B, Tiwary P, Tiwary NK, Singh R, Koirala K, Boelaert M, Rijal S, Sundar S., (2013) J Clin Microbiol., 51(12): 3955-9.. DOI: 10.1128/JCM.01232-13

  1. Oxabicyclo derivatives as novel antileishmanial compounds: Prakash Saudagar, Vikash Kumar Dubey, Anil Kumar Saikia, Pipas Saha, Shyam Lal Mudavath and Shyam Sundar, (2013) 863/KOL/2013 (Indian Patent), NA: NA. DOI: NA

  1. Bioimmunotherapy with Recombinant Mouse Granulocyte-Macrophage Colony-Stimulating Factor (Rm GM-CSF) and Melatonin against Experimental Visceral Leishmaniasis: Ganesh Yadagiri, Om Prakash Singh, Shyam Sundar,Shyam Lal Mudavath*, (2020) SSRN, . DOI: https://ssrn.com/abstract=3534231

  2. An oral formulation of Amphotericin B for the treatment of visceral Leishmaniasis: f-Gr-AmB: M Talat, M Rai, ON Srivastava, S Sundar, (2016) International Journal Of Infectious Diseases, 45: 3067. DOI: 10.1016/j.ijid.2016.02.790

  3. Amine modified graphene mediated drug delivery of Amphotericin B for the treatment of visceral leishmaniasis: M. Rai, M. Talat, O.N. Srivastava, S. Sundar, (2014) International Journal of Infectious Diseases, 21S: 1–460. DOI: 10.1016/j.ijid.2014.03.753

Fundings

  • Citric acid induced self-assemble bubble carrier system to enhance the oral bioavailability of poorly aqueous soluble drugs 3 Yrs, SERB (DST)
    Funding Amount: 4708840
    PI: Dr. Shyam Lal M
  • Development of modified lipid nanovesicles based oral drug delivery system for the treatment of visceral leishmaniasis 3 Years, SERB (DST)
    Funding Amount: 4945968
    PI: Dr. Shyam Lal M

  • 2015

    Ph.D Biochemistry

    Department of Medicine, Institute of Medical Sciences, Banaras Hindu University, Varanasi, Uttar Pradesh, India

  • 2009

    M.Sc Biochemistry

    Department of Biochemistry, School of Life Sciences, University of Hyderabad, Gachibowli, Andhra Pradesh, India

  • 2007

    B.Sc Biotechnology

    Osmania University, Hyderabad, Andhra Pradesh, India

  • Scientist C:Institute of Nano Science and Technology, Habitat Centre, Phase- 10, Sector- 64, Mohali - 160062, Punjab, India (January 2019 to Present till date )

  • Scientist B:Institute of Nano Science and Technology, Habitat Centre, Phase- 10, Sector- 64, Mohali - 160062, Punjab, India (February 2015 to December 2018 )

Awards & Honours

  • Awarded Early Career Research Award by SERB, DST, GOI.

  • Awarded Bill Melinda Gates-ICID Travel Grant for presenting work at ICID March 2-5, 2016, Hyderabad, India.

  • Awarded International Travel Award from ICMR for presenting work at International Congress & Exhibition on Nanobiotechnology organized by Centre of Nanotechnology from June 2- 4th 2014 in Munster, Germany.

  • Awarded Rajiv Gandhi National Fellowship 2011-12 by University Grants Commission, New Delhi, India for pursuing Ph.D.


Professional Recognitions

© Copyright Institute of Nano Science and Technology 2014 - 2021 All Rights Reserved With Institute of Nano Science and Technology